A Study of Oral Ergocalciferol to Treat Pruritis in Hemodialysis Patients (CRN11)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01114672|
Recruitment Status : Completed
First Posted : May 3, 2010
Results First Posted : February 12, 2013
Last Update Posted : February 21, 2013
Pruritis (itching) is common in many people with chronic renal failure on hemodialysis. There may be many different reasons for the pruritis. Efforts to treat the problem have not been very effective.
Vitamin D levels have been found to be low in many hemodialysis patients. Since vitamin D plays an important role in the skin and is effective in treatment of certain skin conditions that involve pruritis, it may have a role in treatment of pruritis in hemodialysis patients.
The objective of the investigators study is to determine the effect of supplementation with oral vitamin D2 (ergocalciferol) on pruritis in hemodialysis patients.
|Condition or disease||Intervention/treatment||Phase|
|Pruritis||Drug: 50,000 Units Ergocalciferol Drug: Placebo||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||50 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Randomized Prospective, Double-Blind Placebo Controlled Study of Oral Ergocalciferol in the Treatment of Pruritis in Hemodialysis Patients|
|Study Start Date :||July 2010|
|Actual Primary Completion Date :||November 2011|
|Actual Study Completion Date :||February 2012|
|Active Comparator: Ergocalciferol||
Drug: 50,000 Units Ergocalciferol
50,000 Units oral ergocalciferol to be given once weekly
|Placebo Comparator: oral placebo||
oral placebo once weekly
- Severity of Pruritis [ Time Frame: Baseline and end of study (up to 12 weeks) ]
Randomized patients will fill out a survey with questions about the degree and location of their pruritis at baseline and end of study. The total score ranged from 0-21 with 21 being the most severe and zero being the absence of any of the measures of pruritis.
Last observation was carried forward to end of study. A decrease in the Severity of Pruritis score over time indicated an improvement in the severity of pruritis.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01114672
|United States, New York|
|Winthop Univ Hospital Outpatient Dialysis at Bethpage|
|Bethpage, New York, United States, 11714|
|Winthrop Univ Hospital Outpatient Dialysis|
|Mineola, New York, United States, 11501|
|Study Director:||Steven Fishbane, MD||Department of Nephrology, Winthrop Univ Hospital|
|Principal Investigator:||Mary Schanler, MS, RD||Winthrop University Hospital, Outpatient Dialysis|